| Bioactivity | Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction[1][2]. | |||||||||
| Name | Larixyl acetate | |||||||||
| CAS | 4608-49-5 | |||||||||
| Formula | C22H36O3 | |||||||||
| Molar Mass | 348.52 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Urban N, et al. Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. Mol Pharmacol. 2016 Jan;89(1):197-213. [2]. Chen X, et al. The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction. J Neuroinflammation. 2019 Jan 31;16(1):21. |
Larixyl acetate
CAS: 4608-49-5 F: C22H36O3 W: 348.52
Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP a
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.